Staging & longitudinal measurement

Using our multivariate advances, we have characterized brain metabolism patterns across the progression from Normal, amyloid negative status through progressively severe stages of MCI and AD.  We have applied similar techniques to provide a more sensitive, powerful measure of longitudinal progression in patients, which can be applied to drug studies.

Quantifying AD disease progression

Above is an example of the characterization of progression from Normal to AD.  As subjects increase in disease severity, hypometabolism in the regions shown becomes more severe.  A patient can be scored quantitatively against this and other patterns, providing greater sensitivity and statistical power than conventional region-of-interest (ROI) measurement techniques.